产品说明书

Miglitol

Print
Chemical Structure| 72432-03-2 同义名 : 米各尼醇 ;BAY1099;BAY-m1099;Seibule;Glyset;Diastabol
CAS号 : 72432-03-2
货号 : A159516
分子式 : C8H17NO5
纯度 : 98%
分子量 : 207.22
MDL号 : MFCD28142869
存储条件：

粉末 Sealed in dry,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

H2O: 200 mg/mL(965.16 mM)
动物实验配方：
生物活性
描述 Miglitol is an alpha glucosidase inhibitor which delays intestinal absorption of carbohydrates and is used as an adjunctive therapy in the management of type 2 diabetes[3]. Miglitol is an oral anti-diabetic drug that acts by inhibiting the ability of the patient to breakdown complex carbohydrates into glucose. The administration of miglitol significantly decreased the levels of plasma glucose, glycoalbumin and high-sensitivity C-reactive protein, and elevated the high-density lipoprotein-cholesterol level in fatty rats[4]. Miglitol appears to safely ameliorate NASH (steatohepatitis) activity by attenuation of steatosis and lobular/portal inflammation[5]. In the intestine, miglitol treatment significantly suppressed the mRNA expression of apical sodium-dependent bile acid transporter and ATP-binding cassette transporter G5 and G8. In fecal microbiome, the prevalence of prevotella was remarkably reduced and that of clostridium subcluster XIVa was increased by miglitol[6]. Long-term miglitol treatment dose-dependently prevented diet-induced obesity and induced mitochondrial gene expression in brown adipose tissue. Miglitol effectively stimulated energy expenditure in mice fed a high-fat high-monocarbohydrate diet, and intraperitoneal injection of miglitol was sufficient to stimulate energy expenditure in mice[7]. Moreover, miglitol can protect against age-dependent weight gain[8].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01697592 - Completed - -
NCT03492580 - Completed - United States, New Jersey ... 展开 >> Janssen Investigative Site Titusville, New Jersey, United States, 08560 收起 <<
NCT02456428 - Completed - Canada, Quebec ... 展开 >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

4.83mL

0.97mL

0.48mL

24.13mL

4.83mL

2.41mL

48.26mL

9.65mL

4.83mL
参考文献

[1]Hirose S, Iwahashi Y, et al. Concurrent Therapy with a Low-carbohydrate Diet and Miglitol Remarkably Improved the Postprandial Blood Glucose and Insulin Levels in a Patient with Reactive Hypoglycemia due to Late Dumping Syndrome. Intern Med. 2016;55(9):1137-42.

[2]Joubert PH, Foukaridis GN, Bopape ML. Miglitol may have a blood glucose lowering effect unrelated to inhibition of alpha-glucosidase. Eur J Clin Pharmacol. 1987;31(6):723-4.

[3]LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Miglitol. 2021 Jan 12

[4]Hirata A, Igarashi M, Iwai H, Tominaga M. Effect of miglitol, an alpha-glucosidase inhibitor, on atherogenic outcomes in balloon-injured diabetic rats. Horm Metab Res. 2009 Mar;41(3):213-20

[5]Komatsu M, Tanaka N, Kimura T, Fujimori N, Sano K, Horiuchi A, Sugiura A, Yamazaki T, Shibata S, Joshita S, Umemura T, Matsumoto A, Tanaka E. Miglitol attenuates non-alcoholic steatohepatitis in diabetic patients. Hepatol Res. 2018 Dec;48(13):1092-1098

[6]Hamada Y, Goto M, Nishimura G, Nagasaki H, Seino Y, Kamiya H, Nakamura J. The alpha-glucosidase inhibitor miglitol increases hepatic CYP7A1 activity in association with altered short-chain fatty acid production in the gut of obese diabetic mice. Metabol Open. 2020 Jan 11;5:100024

[7]Sasaki T, Shimpuku M, Kitazumi T, Hiraga H, Nakagawa Y, Shibata H, Okamatsu-Ogura Y, Kikuchi O, Kim HJ, Fujita Y, Maruyama J, Susanti VY, Yokota-Hashimoto H, Kobayashi M, Saito M, Kitamura T. Miglitol prevents diet-induced obesity by stimulating brown adipose tissue and energy expenditure independent of preventing the digestion of carbohydrates. Endocr J. 2013;60(10):1117-29

[8]Sasaki T, Hiraga H, Yokota-Hashimoto H, Kitamura T. Miglitol protects against age-dependent weight gain in mice: A potential role of increased UCP1 content in brown adipose tissue. Endocr J. 2015;62(5):469-73